Paul Edward Kelly

Paul Edward Kelly is a declared insider of Relmada Therapeutics, Inc. (board member), with filings sourced from SEC (Form 4). Over a trading history stretching from 14 December 2015 to 5 November 2025, the count stands at 50 filings.

On the open market, the record shows 19 purchases worth €676k and 18 sales worth €993k. Sales outweigh purchases by €316k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant and 11 option exercises. Since January 2025: 2 purchases and no sales on the market.

A typical purchase (the median) is worth €6,855. Of 13 purchases, 10 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 19 purchases show a median change of +22.7%, with the price up in 63% of them. They describe history only and say nothing certain about the share price ahead.

On 6 November 2025 came the latest disclosure, an open-market purchase for €172k in Relmada Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.